Analyst Price Targets — MCK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 19, 2026 9:29 am | Glen Santangelo | Barclays | $1,000.00 | $869.26 | TheFly | McKesson price target raised to $1,000 from $925 at Barclays |
| August 19, 2026 7:07 am | Ryan Halsted | RBC Capital | $845.00 | $869.26 | StreetInsider | RBC Capital Starts McKesson (MCK) at Sector Perform |
| August 11, 2026 10:56 am | Stephan Baxter | Wells Fargo | $933.00 | $879.87 | StreetInsider | McKesson (MCK) PT Raised to $933 at Wells Fargo |
| August 6, 2026 1:23 pm | — | Robert W. Baird | $1,015.00 | $843.89 | TheFly | McKesson price target raised to $1,015 from $955 at Baird |
| May 8, 2026 2:52 pm | Kevin Caliendo | UBS | $1,050.00 | $744.46 | TheFly | McKesson price target raised to $1,050 from $1,000 at UBS |
| May 8, 2026 12:53 pm | George Hill | Deutsche Bank | $875.00 | $763.90 | TheFly | McKesson price target lowered to $875 from $973 at Deutsche Bank |
| March 5, 2026 3:28 pm | — | Raymond James | $970.00 | $930.31 | StreetInsider | BofA Securities Reiterates Buy Rating on McKesson (MCK) amid CFO retirement |
| March 5, 2026 2:31 pm | Michael Cherny | Leerink Partners | $1,085.00 | $930.22 | StreetInsider | Leerink Partners Reiterates Outperform Rating on McKesson (MCK) following CFO retirement announcement |
| February 18, 2026 10:11 am | — | Barclays | $1,050.00 | $946.47 | TheFly | McKesson price target raised to $1,050 from $960 at Barclays |
| January 29, 2026 12:20 pm | — | Morgan Stanley | $966.00 | $826.62 | TheFly | McKesson price target raised to $966 from $916 at Morgan Stanley |
Latest News for MCK
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an American healthcare company in recent months.
Beacon Pointe Advisors LLC purchased a new position in shares of McKesson Corporation (NYSE: MCK) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,343 shares of the company's stock, valued at approximately $15,371,000. A number of other hedge funds and
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.